A procedure used to screen embryos for abnormal numbers of chromosomes should no longer be used outside clinical trials, experts have said.
The technique, which is used to increase the chances of older women having children, does not appear to increase pregnancy success rates for over-35s who are undergoing infertility treatment, the British Fertility Society (BFS) has said.
Under new guidelines, the society warns that preimplantation genetic screening (PGS) may even reduce the chances of pregnancy in some cases and should therefore only be used in clinical trials until further research has been carried out.
The new guidelines are published in the journal Human Fertility and author Professor Richard Anderson, from the University of Edinburgh's Centre for Reproductive Biology, confirmed that the technique should only be offered 'within the context of robustly designed randomised trials performed in experienced centres'.
'Following a thorough analysis of the published research, it is clear that there is currently no compelling evidence that PGS improves the clinical pregnancy rate or live birth rate or that it reduces the miscarriage rate,' he said.
"Patients should be clearly advised that there is currently no evidence that PGS will improve their chances of becoming pregnant.